GlassScriptPhysician profile
Ledy T Ochoa
NPI 1740609072
$7,028.25
in general payments reported to CMS, 2019-2025
22 companies · $3,362 in 2025
The $3,362 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $809 · 2022: $467 · 2023: $1,220 · 2024: $1,170 · 2025: $3,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,576 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,576.31 |
| Education | $175.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,145.30 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $982.21 | 2021-2025 | Dupixent |
| Pfizer INC. | $732.58 | 2021-2025 | |
| Galderma Laboratories, L.P. | $600.07 | 2023-2025 | Nemluvio, Aklief |
| Abbvie INC. | $578.81 | 2023-2025 | |
| Incyte Corporation | $564.82 | 2023-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $551.97 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $512.79 | 2021-2025 | |
| Janssen Biotech, INC. | $415.45 | 2021-2023 | Tremfya |
| Lilly USA, LLC | $208.14 | 2021-2025 | Ebglyss |
| Ucb, INC. | $141.75 | 2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $124.52 | 2021 | |
| Dermavant Sciences, INC. | $108.97 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.49 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $50.42 | 2021 | |
| Lnhc, INC | $48.01 | 2025 | Zelsuvmi |
| Novartis Pharmaceuticals Corporation | $38.55 | 2021-2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $37.37 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $27.18 | 2023 | Ycanth |
| Mayne Pharma Commercial LLC | $14.15 | 2025 | |
| Organon LLC | $9.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ledy Ochoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.